Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel: a commentary.
Pharmacoeconomics and Formulary Management, Veterans Affairs San Diego Healthcare System, 3350 La Jolla Village Drive (119), San Diego, CA 92161, USA. Nermeen.Madkour@va.gov
Nermeen
N
Madkour
Mark
M
Bounthavong
D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D006801:Humans; D010879:Piperazines / Q000191:economics* / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000191:economics* / Q000627:therapeutic use*; D013876:Thiophenes / Q000191:economics* / Q000627:therapeutic use*; D015912:Thrombolytic Therapy / Q000191:economics*; D013988:Ticlopidine / Q000031:analogs & derivatives*
D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D013876:Thiophenes; D001189:Aryl Hydrocarbon Hydroxylases; D013988:Ticlopidine